These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 11247328

  • 21. Carboxyterminal type I procollagen peptide concentrations in systemic sclerosis: higher levels in early diffuse disease.
    Scheja A, Hellmer G, Wollheim FA, Akesson A.
    Br J Rheumatol; 1993 Jan; 32(1):59-62. PubMed ID: 8422562
    [Abstract] [Full Text] [Related]

  • 22. Clinical correlations of potential activity markers in systemic sclerosis.
    Becvár R, Stork J, Pesáková V, Stánová A, Hulejová H, Rysová L, Zatloukalová A, Zatloukal P, Jáchymová M, Pourová L.
    Ann N Y Acad Sci; 2005 Jun; 1051():404-12. PubMed ID: 16126982
    [Abstract] [Full Text] [Related]

  • 23. Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations.
    Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska K.
    Arthritis Rheum; 1990 Mar; 33(3):375-80. PubMed ID: 2317223
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
    Gardinali M, Pozzi MR, Bernareggi M, Montani N, Allevi E, Catena L, Cugno M, Bottasso B, Stabilini R.
    J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
    [Abstract] [Full Text] [Related]

  • 27. Duration of Raynaud's phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients.
    Dziankowska-Bartkowiak B, Zalewska A, Sysa-Jedrzejowska A.
    Med Sci Monit; 2004 May; 10(5):CR202-8. PubMed ID: 15114270
    [Abstract] [Full Text] [Related]

  • 28. Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis.
    Sato S, Nagaoka T, Hasegawa M, Nishijima C, Takehara K.
    Dermatology; 2000 May; 200(3):196-201. PubMed ID: 10828626
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Increased levels of type I and III collagen and hyaluronan in scleroderma skin.
    Søndergaard K, Heickendorff L, Risteli L, Risteli J, Zachariae H, Stengaard-Pedersen K, Deleuran B.
    Br J Dermatol; 1997 Jan; 136(1):47-53. PubMed ID: 9039294
    [Abstract] [Full Text] [Related]

  • 33. Circulating Collagen Metabolites and the Enhanced Liver Fibrosis (ELF) Score as Fibrosis Markers in Systemic Sclerosis.
    Chen C, Wang L, Wu J, Lu M, Yang S, Ye W, Guan M, Liang M, Zou H.
    Front Pharmacol; 2022 Jan; 13():805708. PubMed ID: 35177989
    [Abstract] [Full Text] [Related]

  • 34. The clinical significance of serum N-terminal pro-brain natriuretic peptide in systemic sclerosis patients.
    Choi HJ, Shin YK, Lee HJ, Kee JY, Shin DW, Lee EY, Lee YJ, Lee EB, Song YW.
    Clin Rheumatol; 2008 Apr; 27(4):437-42. PubMed ID: 17899307
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Analytical, physiologic, and clinical validation of a radioimmunoassay for measurement of procollagen type III amino terminal propeptide in serum and bronchoalveolar lavage fluid obtained from dogs.
    Schuller S, Valentin S, Remy B, Jespers P, Foulon S, Van Israël N, Clercx C, McEntee K.
    Am J Vet Res; 2006 May; 67(5):749-55. PubMed ID: 16649905
    [Abstract] [Full Text] [Related]

  • 37. Immunologic parameters in systemic sclerosis.
    Bruns M, Herrmann K, Haustein UF.
    Int J Dermatol; 1994 Jan; 33(1):25-32. PubMed ID: 8112935
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.